SOF/VEL

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 3	NCT02607800 Comparator	Nov 2015 → Oct 2016	chronic hepatitis C virus infection	Gilead Sciences	Completed	Missed primary

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	SOF/VEL	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02607800 ↗
Known as	sofosbuvir-velpatasvir	“In 2 phase 3, open-label trials, patients with HCV infection who had not been treated previously with a direct-acting antiviral agent were assigned randomly to groups given...” PMID 28390869 ↗ Apr 2017
Action	Inhibit	“Patients with chronic hepatitis C virus (HCV) infection have high rates of sustained virologic response (SVR) after 12 weeks of treatment with the nucleotide polymerase...” PMID 28390869 ↗ Apr 2017
Route	Oral	“400/100 mg tablet administered orally once daily with or without food” NCT02607800 ↗